But, it hasn’t been clear if the center risk is better for women or guys, the Chinese researchers said. Dong and colleagues reviewed 19 conducted tests done between 1966 and 2014 previously. Combined, the research had almost 11 million people from North America, European countries and Asia. Among these people, more than 106,000 fatal or non-fatal heart attacks or chest pain events occurred, the study said. The researchers found that women with diabetes had a 38 % greater risk of heart attack or angina than men with diabetes did.4 In prior trials, the subcutaneous administration of 60 mg of denosumab every 6 months reduced bone turnover and increased bone mineral density. 5-8 the result was tested by us of denosumab on the risk of fracture in postmenopausal females with osteoporosis. Methods Study Design Our research, called Fracture Reduction Evaluation of Denosumab in Osteoporosis Every six months , was a global, randomized, placebo-controlled trial. Topics were randomly designated to receive subcutaneous injections of either 60 mg of denosumab or placebo at research sites every 6 months for thirty six months.